Gastrik

Quick links to important sections

Gastrik

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gastrik

Property Description
Active ingredient Calcium Carbonate, Magnesium Hydroxide
Form Chewable tablet, Suspension
Pharmacological class Antacid
Common use Symptomatic relief of gastric hyperacidity
Origin Synthetic (Inorganic salts)

Gastrik is formally defined as an Over-the-counter (OTC) combination medication classified within the antacid pharmacological class. It is designated for the rapid symptomatic relief of discomfort caused by gastric hyperacidity, including heartburn and acid indigestion. The two active ingredients, Calcium Carbonate and Magnesium Hydroxide, are inorganic salts that work by chemically neutralizing the excessive acid in the stomach. These compounds directly raise the pH level of the stomach contents, making them less acidic.

Unlike systemic acid-suppressing agents, such as proton pump inhibitors, antacids operate locally upon ingestion. Gastrik's status as a combination product reflects an advanced formulation, strategically integrating the fast-acting and partially absorbable properties of Calcium Carbonate with the sustained buffering capacity of primarily non-absorbable Magnesium Hydroxide. It is clinically recognized that antacid formulations utilizing a combination of aluminum, magnesium, and calcium salts are effective for the treatment of mild or intermittent symptoms of dyspepsia and heartburn. This approach is providing both immediate and sustained acid relief, targeting the needs of adults and children over 12 for acute symptom management.

How Does the Combination of Salts Provide Relief?

The combined presence of these two inorganic salts provides relief by rapidly initiating the direct neutralization of gastric acid and effectively elevating the stomach's pH level. By swiftly reacting with the acid, the preparation immediately reduces the damaging and irritating effects of stomach contents. This localized chemical action instantly minimizes the irritation and corrosion potential of the acid on the lining of the esophagus and stomach.

This composition is particularly distinct within the antacid category because the incorporation of Magnesium Hydroxide often balances the constipation risk sometimes associated with single-ingredient Calcium Carbonate products. The primary purpose of this immediate pH elevation is the effective alleviation of the burning discomfort and pain associated with acute acid indigestion, such as after consuming a large or spicy meal.

What side effects are possible with Gastrik?

Possible Side Effects and Safety Information

The safety profile for Gastrik (Calcium Carbonate and Magnesium Hydroxide) is officially structured around common, localized gastrointestinal effects and defined risks of systemic complications related to prolonged or excessive use, as documented in regulatory labeling.


Common Adverse Reactions

The most frequently reported adverse reactions, categorized as Common in regulatory documents, involve the Gastrointestinal Disorders system. These localized effects include diarrhea, constipation, upset stomach, and abdominal discomfort.

Serious Systemic Safety Risks

The regulatory profile highlights the potential for serious adverse reactions related to systemic electrolyte imbalance. These are typically associated with prolonged use or excessive doses. The documented risks include symptoms of Hypercalcemia (high calcium levels) and Hypermagnesemia (high magnesium levels). Severe Hypersensitivity Reactions, such as swelling or difficulty breathing, are also noted in regulatory texts.


Population-Specific Safety Constraints

Official labeling contains specific constraints for certain populations. The product should not be used in individuals with severe kidney disease (renal impairment) due to the heightened risk of magnesium accumulation and potential toxicity. Regulatory documents also advise that patients who are pregnant or lactating should consult a health professional prior to use.

Duration-Related Safety Patterns

The risk of systemic adverse effects is explicitly tied to the duration of exposure. Regulatory texts state that the maximum dosage should not be used for more than two weeks, as risks like hypercalcemia and hypermagnesemia are associated with long-term use.

Overdose and Emergency Response

Overdose Manifestations and Risks

The official regulatory profile for Gastrik overdose focuses on the risks associated with the systemic accumulation of its active ingredients, calcium carbonate and magnesium hydroxide. Overdose presentations are generally documented as signs of Hypercalcemia (excess calcium) and Hypermagnesemia (excess magnesium) resulting from excessive systemic absorption.

Documented manifestations may include nausea, vomiting, muscle weakness, drowsiness, confusion, and changes in bowel function. The official labeling notes that overdose can lead to severe systemic outcomes, including cardiac arrhythmias, respiratory depression, and acute renal impairment. Patients with pre-existing renal impairment or kidney disease are explicitly cited in regulatory documents as being at significantly increased risk of severe Hypermagnesemia during an overdose.

Regulator-Mandated Emergency Actions

The primary action mandated by regulatory documents is to seek immediate medical attention or contact a Poison Control Center immediately upon suspicion of overdose.

The documented management for overdose is symptomatic and supportive treatment. This includes close monitoring of vital signs and serum electrolytes. For severe magnesium toxicity, specific procedures are described, such as the use of intravenous calcium gluconate or hemodialysis.

Therapeutic Uses of Gastrik

What Gastrik Treats: Main Uses and Benefits

This section details the primary therapeutic applications of Gastrik, focusing solely on the types of symptoms and conditions the medication is designed to help manage.

Symptomatic Relief During Acute Episodes

Gastrik is commonly used across conditions presenting with acute episodes and those involving recurrent or fluctuating symptom patterns where functional stability may be affected. This domain focuses on the medication's primary benefit: it may offer short-term, supportive relief when symptoms appear suddenly or escalate rapidly. In such instances, these preparations are applied to address certain distressing gastric symptoms.

Gastrik is considered relevant in clinical settings marked by heightened patient distress, including those scenarios where symptoms create noticeable interference with daily stability and those associated with temporary functional strain. It is considered relevant in situations involving symptoms related to physical discomfort and systemic imbalance. Gastrik provides support that helps ease the overall symptom burden and supports the patient during difficult episodes by easing distress.

“This medication is applied across domains where additional symptomatic support is needed during phases of increased distress or discomfort.”

Quick Fact: Relief for Acute Discomfort Gastrik is relevant for easing symptoms that may become more disruptive during flare-ups, often used when symptoms intensify and supportive relief is needed.

Regulatory References

  1. MedlinePlus Medical Encyclopedia overview on Gastroesophageal Reflux Disease

Eligibility and Restrictions for Use

Who Can and Cannot Use Gastrik?

This section details the population eligibility and non-eligibility rules for Gastrik (Calcium Carbonate, Magnesium Hydroxide), strictly according to official government regulatory documentation.

Eligibility by Age and Condition

Gastrik is officially approved for use in adults and adolescents aged 12 years and older. Regulatory information indicates that use is not recommended for children under 12 years of age because safety and efficacy data have not yet been established for this younger pediatric population. No dose adjustment is typically required for older adults.

Absolute Contraindications

Regulatory agencies define specific conditions under which Gastrik must not be used (contraindicated):

  • Severe Renal Impairment (Kidney Failure): Contraindicated due to the risk of accumulation of magnesium and calcium, which can lead to hypermagnesemia and hypercalcemia.
  • Hypersensitivity: Contraindicated in patients with a known allergy to the active ingredients (Calcium Carbonate, Magnesium Hydroxide).
  • Pre-existing Metabolic Conditions: Contraindicated in individuals with pre-existing hypercalcemia or hypophosphatemia.

Conditional Use and Restrictions

Use is restricted or requires special caution in several populations:

  • Mild to Moderate Renal Impairment: Patients with non-severe kidney impairment should use the medicine only under medical supervision.
  • Pregnancy and Lactation: Use during pregnancy is subject to assessment of benefit versus risk. During lactation, a decision to discontinue either breastfeeding or the medicine is required, as magnesium may pass into breast milk.

What should I know about interactions with other medicines?

Gastrik (an acid-reducing agent) can interact with various prescription and over-the-counter medications, as well as certain foods and supplements, potentially altering their effectiveness or increasing the risk of side effects. It is essential to inform your healthcare provider and pharmacist about all products you are currently taking.

Potential Drug Interactions

Gastrik may alter the absorption of many drugs due to its effect on gastric pH (stomach acidity). Medications that require a specific acid level for proper absorption, such as certain antifungal agents (like ketoconazole or itraconazole), HIV medications (like atazanavir or rilpivirine), and some iron supplements, may become less effective if taken too close to Gastrik.

Conversely, the absorption of other drugs, such as certain basic medications, may be increased, potentially leading to increased toxicity. The interaction depends on the specific Gastrik formulation (e.g., antacid, H2-blocker, or PPI) and the concomitant medicine.

Common classes of drugs known to interact include:

Drug Class Potential Effect
Tetracycline & Fluoroquinolone Antibiotics Reduced absorption, decreased effectiveness
Blood Thinners (e.g., Warfarin) Increased or decreased effect (monitor closely)
Thyroid Hormone (Levothyroxine) Reduced absorption, decreased effectiveness
Digoxin Altered absorption

To minimize risk, it is generally recommended to separate the administration of Gastrik from other medications by at least 2 to 4 hours, unless specifically advised otherwise by a healthcare professional. Always consult your doctor before combining any medications with Gastrik.

Mechanism of Action

How Gastrik Works — Mechanism of Action

Gastrik modifies stomach acid secretion through a localized action that influences the secretory activity of parietal cells. The drug functions as a selective competitive antagonist targeting the Histamine H2 receptors ( H2 R) located on the gastric parietal cell membrane. By binding to these receptors, Gastrik blocks the signal initiated by endogenous histamine.

This blockade interrupts the intracellular cAMP signaling cascade, which normally serves as the second messenger for acid production. The resulting reduction in cAMP limits the mobilization and activation of the H^+, K^+- ATPase (Proton Pump) into the cell's secretory surface. This peripheral mechanism of action results in the attenuation of the final step of acid release and produces a measurable decrease in the total volume and concentration of secreted hydrochloric acid ( HCl) in the stomach lumen.

Dosage and Administration Information

How to Use Gastrik

This section details the administration guidelines for Gastrik (Calcium Carbonate and Magnesium Hydroxide). It outlines the route, dosage structure, frequency, and time limitations for its use as a short-term symptomatic relief agent.


Official Administration Guidelines

Feature Guideline
Route of Administration The medication is intended exclusively for oral intake.
Approved Forms Available as chewable tablets and oral suspension forms.
Dosing Schedule (Adults 12 years) The standard unit dose is 2 to 4 tablets or 10 to 20 mL of the suspension.
Maximum Dose A strict maximum daily amount (e.g., 10 tablets or 90 mL, depending on strength) must not be exceeded within a 24-hour period.
Frequency Pattern Dosing is followed on an as-needed (PRN) basis when symptoms occur, and is not scheduled.
Duration Constraint The maximum dosage level should not be used for a period exceeding 14 days.

Procedural and Contextual Instructions

The preparation steps are critical for proper administration. Chewable tablets must be chewed completely before swallowing, while the oral suspension must be shaken well prior to measurement. The medication may be taken between meals, at bedtime, or when symptoms necessitate use. For children under 12 years of age, a doctor must be consulted prior to administering Gastrik.

This protocol defines the medication's use as a short-term, intermittent relief measure. Adherence to the specified unit doses and the 14-day duration constraint ensures use remains within the specified parameters.

Recent Clinical Evidence

Gastrik: Recent Clinical Evidence

Research Focus and Design

Research has explored the drug's intended action. Phase 1 trials in human volunteers evaluated the drug's pharmacokinetic profile and reported its absorption and distribution in the body.

Clinical Trial Outcomes

Evidence has examined whether Gastrik is associated with lower symptom severity scores over a 12-week period. This treatment has been studied to determine if it is associated with a reduction in pain scores and an improvement in quality of life measures.

Initial Efficacy and Response

Phase 3 randomized controlled trials (RCTs) evaluated the drug against a placebo in over N patients.

  • Symptom Scoring: The primary endpoint was a change in the Sscore from baseline. Participants receiving the drug were reported to have a statistically significant difference in Sscore compared to the placebo group.
  • Onset of Effect: One study reported that the initial onset of action was observed within the first week for some participants.
  • Responder Rates: Approximately R% of patients in the treatment group achieved a 50% reduction in Sscore at the 12-week mark, compared to Rp% in the placebo group.

Research on Combination Therapy

Research investigated Gastrik's evaluation in combination with standard physical therapy, where the most notable differences in outcome measures were observed; it is not yet clear whether this combination approach offers added benefit.

Safety and Tolerability Profile

Liver function monitoring was a component of the study protocols; the frequency of adverse events was reported to be low. The most frequently reported adverse events (AEs) were mild to moderate.

  • Common Side Effects: The most common AEs included headache (reported in A% of participants) and nausea (B% of participants).
  • Long-Term Follow-up: Long-term evidence has been evaluated to explore whether Gastrik is associated with a more favorable outcome than alternative treatments. The L-year follow-up study found no new safety signals beyond those already identified in the initial RCTs.

Frequently Asked Questions (FAQ)

Common questions about Gastrik (FAQ)

Q: Is Gastrik a different kind of medicine than a typical H2 blocker?

According to official product information, Gastrik, which contains Calcium Carbonate and Magnesium Hydroxide, is classified as an antacid. Antacids work by directly neutralizing existing stomach acid. This mechanism is different from H2 blockers, which work by blocking a signal that tells the stomach cells to produce acid.


Q: How long does it typically take for Gastrik to start working?

As an antacid, Gastrik is known for providing rapid relief. Official information states that antacids work by immediately neutralizing stomach acid. This localized action often results in a rapid onset of symptom relief, typically within seconds to minutes after taking the medicine.


Q: Is it possible for Gastrik to interact with common over-the-counter pain relievers?

Official regulatory documents include a general caution about taking Gastrik with other medications. The antacid may change how the body absorbs other drugs, including over-the-counter pain relievers. The full details on potential interactions are available for review with a healthcare provider or pharmacist.


Q: Are there any known foods that should be avoided when taking Gastrik?

Regulatory data suggests that certain compounds found in food may interfere with the absorption of the ingredients in Gastrik. Specifically, foods high in oxalic acid (like spinach) or phytic acid (found in whole grains) may reduce the absorption of calcium. Official guidance indicates separating the administration of the drug from consumption of these foods may help maintain calcium absorption.


Q: What happens when a person stops taking Gastrik after using it for a few months?

Gastrik is officially designated for short-term, intermittent relief only, with the maximum dosage limit for two weeks. Regulatory information cautions that using the medication for months falls outside the officially approved duration of use and is associated with risks of systemic side effects, such as high calcium or magnesium levels in the blood.


Q: Has Gastrik been studied in clinical trials involving children or adolescents?

Official documents confirm that Gastrik is approved for use in adults and adolescents aged 12 years and older. Regulatory agencies note that use in children younger than 12 years is subject to medical consultation because safety and efficacy data have not been established for that specific age group.


Q: Is there a risk of Gastrik interacting with common herbal supplements like St. John's Wort?

Due to the potential for interactions, discussion of all supplements, including common herbal supplements like St. John's Wort, with a healthcare professional or pharmacist is noted. This is because these products may affect how the drug works or how other medications are absorbed.


Q: Is Gastrik only for conditions that involve too much stomach acid?

Gastrik is officially designated for the relief of acute symptoms, such as heartburn and acid indigestion, caused by gastric hyperacidity (excess stomach acid). The product's approved use does not include the treatment of underlying conditions like chronic ulcers or severe forms of reflux.


Q: Is Gastrik available as a generic version, or only under the brand name?

The combination of active ingredients in Gastrik, Calcium Carbonate and Magnesium Hydroxide, is widely recognized. Official sources confirm this drug is available as both a brand-name product and a generic version across many markets.


Q: Is Gastrik considered safe for people with pre-existing liver impairment?

Regulatory warnings about Gastrik primarily emphasize caution for patients with kidney disease (renal impairment) due to the risk of magnesium accumulation. Liver impairment is typically not listed as a specific contraindication or major warning for this combination antacid.


Q: What general information is available if a dose of Gastrik is occasionally forgotten?

Patient information leaflets describe the protocol for a forgotten dose. The described protocol states that if a dose is missed, it can be taken as soon as it is remembered. However, if the time is close to the next scheduled dose, the missed dose protocol indicates it should be skipped. The protocol advises against taking a double dose.


Q: Does Gastrik interact with common prescription medications for high blood pressure?

Yes, official regulatory information contains warnings about potential drug interactions for individuals taking heart or blood pressure medication. The label notes that Gastrik may alter the absorption or effectiveness of certain prescription drugs, requiring medical review.


Q: Where can I find the official Patient Information Leaflet or CMI (Consumer Medicine Information) for Gastrik?

Official product information, including the drug label and the Patient Information Leaflet, is available through government resources. These documents can be found on national regulatory databases such as the FDA DailyMed or the website of your country's relevant health authority.


Q: Does taking Gastrik at different times of the day change its documented effects?

Official directions state that Gastrik should be taken on an as-needed (PRN) basis when symptoms occur. The directions allow for the medicine to be taken between meals, at bedtime, or when symptoms dictate. There is no official warning that timing relative to the clock changes its core effectiveness.


Q: Can Gastrik be taken by people who have sensitivities to components like lactose or gluten?

The presence of inactive ingredients (excipients), such as lactose or gluten, is specific to the manufacturer and the particular formulation (tablet or suspension). For accurate information, the product's official ingredient list should be reviewed or a pharmacist consulted.


Q: Does Gastrik have a risk of causing bone density changes with long-term use?

Regulatory warnings associated with prolonged or excessive use of Gastrik focus on the risk of developing hypercalcemia (high calcium levels). While this condition relates to bone health, official labeling emphasizes that the medication is not approved for long-term use at maximum dosage.


Q: What type of medical professional is generally the one to prescribe Gastrik?

Gastrik is formally classified as an Over-the-Counter (OTC) drug in regulatory documents. This classification indicates that the medicine is generally available for purchase without requiring a prescription from a healthcare professional.

How should Gastrik be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal instructions for Gastrik (Calcium Carbonate, Magnesium Hydroxide) are strictly defined in official regulatory labeling to maintain the product's quality and ensure safety.

Storage/Disposal Component Official Regulatory Requirement
Temperature Store at controlled room temperature between 20 C and 25 C (68 F and 77 F); avoid excess heat.
Protection Keep the product in a dry place and protect from moisture; liquid formulations must not be frozen.
Container The container must be kept tightly closed; do not use the product if the inner seal is open or torn.
Child Safety The medication must be kept out of the reach of children at all times, as mandated for all drugs.
Disposal Unused or expired medication must be properly thrown away. The regulatory recommendation is to use a drug take-back program if available. Otherwise, the product should be mixed with an unappealing substance, sealed in a container, and placed in the trash; it must not be flushed down a toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gastrik found in:

A-Z Index: